Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 16, Issue 9, Pages 1125-1134
Publisher
Informa UK Limited
Online
2016-06-02
DOI
10.1080/14712598.2016.1196182
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Macrophage miRNAs in atherosclerosis
- (2016) Denuja Karunakaran et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Antisense molecules: A new class of drugs
- (2016) Daniel P. Potaczek et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Safety and efficacy of evinacumab, a monoclonal antibody to ANGPTL3, in patients with homozygous familial hypercholesterolemia receiving concomitant lipid-lowering therapies
- (2016) Daniel Gaudet et al. Journal of Clinical Lipidology
- Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism
- (2016) Ilenia Minicocci et al. JOURNAL OF LIPID RESEARCH
- Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results
- (2016) Xiaohong Yang et al. JOURNAL OF LIPID RESEARCH
- Complex effects of inhibiting hepatic apolipoprotein B100 synthesis in humans
- (2016) Gissette Reyes-Soffer et al. Science Translational Medicine
- Lipoprotein(a)
- (2016) Sotirios Tsimikas Current Opinion in Endocrinology Diabetes and Obesity
- Comparative Renal Toxicopathology of Antisense Oligonucleotides
- (2016) Jeffery A. Engelhardt Nucleic Acid Therapeutics
- Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population
- (2016) Pia R. Kamstrup et al. JACC-Heart Failure
- Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With HypercholesterolemiaSignificance
- (2015) Raul D. Santos et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- ISIS-ANGPTL3RX, an antisense inhibitor to angiopoietin-like 3, reduces plasma lipid levels in mouse models and in healthy human volunteers
- (2015) T.A. Brandt et al. ATHEROSCLEROSIS
- Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial
- (2015) Eveline P. van Poelgeest et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro®): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B
- (2015) Richard S. Geary et al. CLINICAL PHARMACOKINETICS
- No effect on QT intervals of mipomersen, a 2′-O-methoxyethyl modified antisense oligonucleotide targeting ApoB-100 mRNA, in a phase I dose escalation placebo-controlled study, and confirmed by a thorough QT (tQT) study, in healthy subjects
- (2015) Rosie Z. Yu et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Oligonucleotide therapeutics: chemistry, delivery and clinical progress
- (2015) Vivek K Sharma et al. Future Medicinal Chemistry
- Nucleic acid-sensing TLRs and autoimmunity: novel insights from structural and cell biology
- (2015) Karin Pelka et al. IMMUNOLOGICAL REVIEWS
- MicroRNA-33–dependent regulation of macrophage metabolism directs immune cell polarization in atherosclerosis
- (2015) Mireille Ouimet et al. JOURNAL OF CLINICAL INVESTIGATION
- Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia
- (2015) Raul D. Santos et al. Journal of Clinical Lipidology
- Efficacy and safety of mipomersen in treatment of dyslipidemia: A meta-analysis of randomized controlled trials
- (2015) Raju Panta et al. Journal of Clinical Lipidology
- Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion
- (2015) Yan Wang et al. JOURNAL OF LIPID RESEARCH
- Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans
- (2015) Mark J. Graham et al. JOURNAL OF LIPID RESEARCH
- Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study
- (2015) Sotirios Tsimikas et al. LANCET
- Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
- (2015) Daniel Gaudet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liver histology during Mipomersen therapy for severe hypercholesterolemia
- (2014) Nikroo Hashemi et al. Journal of Clinical Lipidology
- Discrimination and Net Reclassification of Cardiovascular Risk With Lipoprotein(a)
- (2014) Peter Willeit et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
- (2014) Anders Berg Jørgensen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting APOC3 in the Familial Chylomicronemia Syndrome
- (2014) Daniel Gaudet et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Roles of Individual Mammalian Argonautes in RNA Interference In Vivo
- (2014) Vera M. Ruda et al. PLoS One
- Nucleic acid therapeutics: basic concepts and recent developments
- (2014) Vivek K. Sharma et al. RSC Advances
- The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease
- (2013) Gilbert R. Thompson ATHEROSCLEROSIS SUPPLEMENTS
- Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease
- (2013) Josef Leebmann et al. CIRCULATION
- Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans
- (2013) Mark J. Graham et al. CIRCULATION RESEARCH
- Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension
- (2013) Raul D. Santos et al. EUROPEAN HEART JOURNAL
- Extreme Lipoprotein(a) Levels and Improved Cardiovascular Risk Prediction
- (2013) Pia R. Kamstrup et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Elevated Lipoprotein(a) and Risk of Aortic Valve Stenosis in the General Population
- (2013) Pia R. Kamstrup et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
- (2013) Kevin Fitzgerald et al. LANCET
- Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics
- (2013) Martin A Maier et al. MOLECULAR THERAPY
- MicroRNAs and lipoproteins: A connection beyond atherosclerosis?
- (2012) Giuseppe Danilo Norata et al. ATHEROSCLEROSIS
- Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency
- (2012) Anthony S Wierzbicki et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Inhibition of pre-protein convertase serine kexin-9 (PCSK-9) as a treatment for hyperlipidaemia
- (2012) Anthony S Wierzbicki et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- MicroRNA-27b is a regulatory hub in lipid metabolism and is altered in dyslipidemia
- (2012) Kasey C. Vickers et al. HEPATOLOGY
- Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins
- (2012) Jeremy D. Furtado et al. JOURNAL OF LIPID RESEARCH
- The PCSK9 decade
- (2012) Gilles Lambert et al. JOURNAL OF LIPID RESEARCH
- Lipoprotein(a): Medical Treatment Options for an Elusive Molecule
- (2011) Klaus G. Parhofer CURRENT PHARMACEUTICAL DESIGN
- Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia
- (2011) Fatima Akdim et al. EUROPEAN HEART JOURNAL
- Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
- (2011) M. John Chapman et al. EUROPEAN HEART JOURNAL
- Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis
- (2011) Katey J. Rayner et al. JOURNAL OF CLINICAL INVESTIGATION
- Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides
- (2011) Katey J. Rayner et al. NATURE
- Lipoprotein(a) as a cardiovascular risk factor: current status
- (2010) Børge G. Nordestgaard et al. EUROPEAN HEART JOURNAL
- Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy
- (2010) Stephen J. Nicholls et al. JOURNAL OF LIPID RESEARCH
- Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
- (2010) Frederick J Raal et al. LANCET
- Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
- (2010) Min Jun et al. LANCET
- Future Challenges for Microsomal Transport Protein Inhibitors
- (2009) Anthony Wierzbicki et al. Current Vascular Pharmacology
- Torcetrapib Induces Aldosterone and Cortisol Production by an Intracellular Calcium-Mediated Mechanism Independently of Cholesteryl Ester Transfer Protein Inhibition
- (2009) Xiao Hu et al. ENDOCRINOLOGY
- Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
- (2009) Pia R. Kamstrup JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of CP-532,623 and Torcetrapib, Cholesteryl Ester Transfer Protein Inhibitors, on Arterial Blood Pressure
- (2009) Eileen Blasi et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia
- (2008) Jean-Charles Fruchart et al. AMERICAN JOURNAL OF CARDIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started